Acute and chronic herpes zoster. An ancient scourge yields to timely therapy.
With the US population aging steadily, herpes zoster represents a growing contributor to diminished quality of life. Dermatologic manifestations appear as immunity declines with age but rarely pose a significant threat, except in instances when ocular structures are involved. Pain is of more concern, because it usually accompanies and may even precede and persist after acute eruptions. In most young patients, pain is transient and bearable. Unfortunately, in the elderly--who are at highest risk for herpes zoster--pain is often more prolonged and more intense. In spite of a wide spectrum of interventions, palliative efforts remain rather ineffectual. At present, intervening as early as possible, ideally within 48 to 72 hours of disease onset, offers the greatest chance of minimizing neurologic sequelae. Inoculation with varicella vaccine in patients between ages 55 and 65 may prove to boost cell-mediated immunity sufficiently so that recrudescence of the varicella virus can be relegated to the annals of history.
Landow
K
K
University of Southern California School of Medicine, Los Angeles, USA. drlandow@anv.net
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000208:Acute Disease; D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D000077595:Famciclovir; D006562:Herpes Zoster / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D009437:Neuralgia / Q000821:virology; D012307:Risk Factors; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000998:Antiviral Agents; D015075:2-Aminopurine; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D000212:Acyclovir